# US 8,569,255 B2 · Post-exposure therapy of influenza A infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,255 B2
- Document ID: US8569255B2
- Status: Granted
- Kind: B2
- Application number: 13/364,486
- Filed: 2012-02-02
- Published: 2012-08-02
- Granted: 2013-10-29
- Earliest claimed: 2011-02-02
- Assignees: Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence
- Applicants: Jonathan P. Wong
- Inventors: Jonathan P. Wong
- Web page: https://patentgrep.com/patent/US8569255B2

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- C12N 2760/16171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Poly ICLC or liposome-encapsulated Poly ICLC (LE Poly ICLC) in combination with antisense oligonucleotides (AS) act synergistically in post-exposure prophylaxis or therapy of influenza infections, especially H5N1 virus infections.

## Claims

### Claim 1

A method of treating an influenza virus infection in a subject consisting essentially of administering to the subject, after the subject has been exposed to the influenza virus, a synergistic combination of
Poly ICLC or liposome-encapsulated Poly ICLC (LE Poly ICLC), and
an antisense oligonucleotide comprising the nucleotide sequence as set forth in SEQ ID NO: 4.

### Claim 2 (depends on 1)

The method of claim 1, wherein the synergistic combination comprises the LE Poly ICLC and the antisense oligonucleotide comprising the nucleotide sequence as set forth in SEQ ID NO: 4.

### Claim 3 (depends on 2)

The method of claim 2, wherein the influenza virus is an influenza A virus.

### Claim 4 (depends on 2)

The method of claim 2, wherein the influenza virus is H1N1, H3N2, H5N1 or H5N2 virus.

### Claim 5 (depends on 2)

The method of claim 2, wherein the influenza virus is H5N1 virus.

### Claim 6 (depends on 2)

The method of claim 2, wherein the antisense oligonucleotide is administered in liposome-encapsulated form.

### Claim 7 (depends on 2)

The method of claim 2, wherein the LE Poly ICLC is administered in an amount in a range of from 0.1 to 5 mg/kg body weight of the subject.

### Claim 8 (depends on 2)

The method of claim 2, wherein the antisense oligonucleotide is administered in an amount in a range of from 1 to 50 mg/kg body weight of the subject.

### Claim 9 (depends on 2)

The method of claim 2, wherein the LE Poly ICLC and the antisense oligonucleotide are administered to the subject within 2 hours of each other.

### Claim 10 (depends on 2)

The method of claim 2, wherein the LE Poly ICLC and the antisense oligonucleotide are administered to the subject simultaneously.

### Claim 11 (depends on 2)

The method of claim 2, wherein the LE Poly ICLC and the antisense oligonucleotide are administered intranasally.

### Claim 12 (depends on 11)

The method of claim 11, wherein intranasal the administration is accomplished with an aerosol.

### Claim 13 (depends on 2)

The method of claim 2, wherein the subject is human.